soul trial oral semaglutide cardiovascular outcomes results 2024 nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes Canadian Perspectives 2025 Whiteboard on

Nordmann R

Joshi S, Peck AB, Khan SR (2013) NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys

Retatrutide + MOTS-c adds a mitochondrial-derived peptide to support cellular fat oxidation and lean mass through AMPK - useful when the limit is metabolic adaptation, fatigue, or lean-mass concerns rather than appetite

This mechanism explains the rapid rise of GLP-1 weight loss treatments in metabolic medicine

Nullam imperdiet diam ut neque ullamcorper semper

FRIDAY, March 6, 2026 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with reduced asthma exacerbation risk among individuals with overweight or obesity, without diabetes, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb